icon-folder.gif   Conference Reports for NATAP  
 
  64rd Annual Meeting of the
American Association for the
Study of Liver Diseases
Washington, DC Nov 1-5 2013
Back grey_arrow_rt.gif
 
 
 
Efficacy and Safety of an Interferon-Free Regimen of MK-5172 + Ribavirin for 12 Weeks or 24 Weeks in Treatment-Naive, Noncirrhotic Subjects With HCV GT1 Infection: The C-SPIRIT Study
 
 
  Reported by Jules Levin
AASLD 2013 Oct 1-4 Wash DC
 
Edward Gane,1 Ziv Ben Ari,2 Lindsay Mollison,3 Eli Zuckerman,4 Rafael Bruck,5 Yaacov Baruch,6 Janice Wahl,7 Sanhita Bhanja,7 Peggy Hwang,7 Yue Zhao,7 Michael N. Robertson7
1Auckland Clinical Studies, Grafton, Auckland, New Zealand; 2 Liver Disease Center, Sheba Medical Center, Ramat Gan, Israel; 3Fremantle Hepatitis Services, Fremantle Hospital, Fremantle, Australia; 4Liver Unit, Carmel Medical Center, Technion Faculty of Medicine, Haifa, Israel;
5Department of Gastroenterology and Liver Diseases, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; 6Liver-Unit, Rambam Health Care Campus, Haifa, Israel; 7Merck & Co., Inc, Whitehouse Station, NJ, USA

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif